Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced the appointment of two key individuals who will assume leadership roles within the company’s commercial organization. Thomas Slubyhas been …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced new data regarding the benefit of EXPAREL®(bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced estimated EXPAREL® (bupivacaine liposome injectable suspension) and total revenues for the fourth quarter and full-year 2015. These estimates, which …
Considerable strength remains visible among biotechnology stocks, as reflected by the 3 percent gain being posted by the iShares NASDAQ Biotechnology Index today. The …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced that it has achieved an amicable resolution with the United States in its lawsuit filed on September 8, 2015, …
Wedbush analyst Liana Moussatos weighed in today with her views on Pacira Pharmaceuticals Inc (NASDAQ:PCRX), as Symphony Health’s EXPAREL volume and sales estimates for August decreased …
Canaccord analyst Corey Davis weighed in today with a favorable report on shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX), reiterating a Buy rating and a price …
